Disease · MONDO_0019079
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Nusinersen vs Sham Procedure: Number of Participants With Abnormal, Clinically Relevant Post-Baseline Worsening in Electrocardiogram (ECG) in Results | 0 of 84 | 2 of 42 | 126 | NCT02292537 | Trial comparisons |
| Nusinersen vs Sham Procedure: Number of Participants Taking Any Concomitant Medication Related to Dosing Procedure or Sham Procedure | 84 of 84 | 42 of 42 | 126 | NCT02292537 | Trial comparisons |
| Nusinersen vs Sham Procedure: deaths from any cause | 0 of 84 | 0 of 42 | 126 | NCT02292537 | Trial comparisons |
| Nusinersen vs Sham Procedure: serious adverse events | 14 of 84 | 12 of 42 | 126 | NCT02292537 | Trial comparisons |
| Nusinersen vs Control: Number of Participants With Clinically Significant Changes From Baseline in Urinalysis Values | 0 of 80 | 0 of 41 | 121 | NCT02193074 | Trial comparisons |
| Nusinersen vs Control: serious adverse events | 61 of 80 | 39 of 41 | 121 | NCT02193074 | Trial comparisons |
| Cohort 1: Bi-allelic Deletions of SMN1 and 2 Copies of SMN2 vs Cohort 2: Bi-allelic Deletions of SMN1 and 3 Copies of SMN2: deaths from any cause | 0 of 14 | 0 of 15 | 29 | NCT03505099 | Trial comparisons |
| Cohort 1: Bi-allelic Deletions of SMN1 and 2 Copies of SMN2 vs Cohort 2: Bi-allelic Deletions of SMN1 and 3 Copies of SMN2: serious adverse events | 5 of 14 | 3 of 15 | 29 | NCT03505099 | Trial comparisons |
| Nusinersen 6 mg vs Nusinersen 12 mg: deaths from any cause | 1 of 4 | 4 of 16 | 20 | NCT01839656 | Trial comparisons |
| Nusinersen 6 mg vs Nusinersen 12 mg: serious adverse events | 3 of 4 | 13 of 16 | 20 | NCT01839656 | Trial comparisons |
| ISIS 396443 Part 1 & 2 vs ISIS 396443 Part 2(Participants on Sham in Part 1): Number of Participants With Plasma Antibodies to ISIS 396443 | 0 of 14 | 0 of 6 | 20 | NCT02462759 | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | 6 of 6 | 7 of 8 | 14 | NCT00528268 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019079/comparisons